------------------------------------------------------ PHARMACEUTICALS related term(s) Drugs Addresses State of the Union: President Trump, S645-S649 [24FE], H2287- H2295 [24FE] Bills and resolutions Centers for Medicare & Medicaid Services: require Center for Medicare and Medicaid Innovation to test model implementing most-favored-nation drug pricing (see H.R. 7837), H2470 [5MR] Courts: establish Federal tort for harm to women caused by chemical abortion drugs (see S. 4066), S1009 [11MR] (see H.R. 7902), H2481 [12MR] Dept. of Defense: improve access to certain medications under TRICARE program (see S. 4106), S1090 [17MR] Dept. of HHS: ensure that Federally-qualified health centers are not required to pay more than 340B ceiling price for covered outpatient drugs at time of purchase (see H.R. 7391), H2040 [5FE] ------ensure that women seeking chemical abortion are made aware of risks involved (see H.R. 7237), H1912 [23JA] ------establish demonstration program to award grants to States to improve provision of recommended immunizations for children, adolescents, and adults through use of mobile vaccination units (see H.R. 7465), H2118 [10FE] ------establish program to develop innovative antimicrobial drugs targeting most challenging pathogens and most threatening infections (see H.R. 7352), H2029 [4FE] ------improve access to pre-exposure prophylaxis (PrEP) to reduce transmission of HIV (see S. 3990), S802 [4MR] (see H.R. 7853), H2471 [5MR] ------provide funding for trained school personnel to administer drugs and devices for emergency treatment of known or suspected opioid overdose (see S. 3588), S89 [7JA] Dept. of Labor: issue guidance and regulations regarding opioid overdose reversal medication and employee training (see S. 3812), S552 [10FE] (see H.R. 7479), H2118 [10FE] Dept. of Veterans Affairs: award grants to develop, implement, and evaluate approaches and methodologies for prospective randomized control trials for neurorehabilitation treatments for chronic mild traumatic brain injury (see H.R. 6993), H615 [9JA] ------improve schedule for rating disabilities (see H.R. 8066), H2675 [24MR] ------make opioid overdose rescue medications available to veterans and their caregivers (see S. 3758), S442 [2FE] Depts. of HHS and State: formulate strategy to secure support from foreign countries, multilateral organizations, and others to facilitate development and commercialization of qualified pandemic or epidemic products (see H.R. 7879), H2476 [9MR] Drugs: mitigate effects of coronavirus pandemic on incentives for development of orphan drugs (see H.R. 7693), H2327 [25FE] ------modify requirements relating to prescription of controlled substances via Internet (see H.R. 6994), H615 [9JA] ------prevent importation of illicit pill press machines with intent to counterfeit substances (see H.R. 7184), H1171 [21JA] ------prohibit certain acts related to fentanyl, analogues of fentanyl, and counterfeit substances (see H.R. 8005), H2620 [19MR] ------reduce price of insulin, require pharmacy benefit managers to pass-through manufacturer rebates for insulin products, and promote generic and biosimilar competition (see S. 4189), S1614 [25MR] FDA: accelerate patient access to innovative medicines and clinical trials for life-threatening diseases by establishing reciprocal approval mechanism with trusted international regulatory authorities (see H.R. 7953), H2550 [17MR] ------enhance ability of outsourcing facilities to mitigate drug shortages by allowing short-term period to continue supplying market after drug is in shortage (see H.R. 7528), H2217 [12FE] ------establish new prohibited acts relative to dietary supplements (see S. 3797), S509 [5FE] (see H.R. 7407), H2041 [5FE] ------expand certain authorities relative to recall of controlled substances to apply to all drugs (see H.R. 7980), H2596 [18MR] ------improve regulation of abortion drugs by prohibiting approval of new drugs, preventing labeling changes of existing drugs, and limiting dispensing of drugs remotely, by mail, or telemedicine (see S. 3697), S290 [27JA] ------require drug labeling to include original manufacturer and supply chain information (see S. 3788), S509 [5FE] ------set forth limitations on exclusive approval or licensure of drugs designated for rare diseases or conditions (see S. 3716), S344 [28JA] ------strengthen regulation of compounding pharmacies and outsourcing facilities (see S. 3794), S509 [5FE] ------withdraw approval of mifepristone for termination of intrauterine pregnancy (see S. 4066), S1009 [11MR] (see H.R. 7902), H2481 [12MR] GAO: conduct study and submit report on price-related compensation and payment structures in prescription drug supply chain (see S. 3751), S377 [29JA] Health: end liability shield for vaccine manufacturers (see S. 3853), S578 [11FE] ------provide private right of action for children and parents of children whose healthy body parts have been damaged by medical professionals practicing or participating in certain interventions (see H.R. 7651), H2258 [23FE] Income: prohibit kickbacks to pharmacy benefit managers (see H.R. 7895), H2481 [12MR] Insurance: ban anticompetitive terms in facility and insurance contracts that limit access to higher quality, lower cost care (see S. 4027), S915 [9MR] ------prohibit pharmacy benefit managers, insurers, and prescription drug or medical device wholesalers from being under common ownership with certain medical service providers (see S. 3822), S552 [10FE] Medicaid: codify value-based purchasing arrangements and reforms relative to price reporting under such arrangements (see H.R. 7871), H2476 [9MR] Medicare: provide coverage for pre-exposure prophylaxis (PrEP) furnished by pharmacists (see H.R. 7189), H1171 [21JA] ------require Medicare Payment Advisory Commission reports to Congress on arrangements with pharmacy benefit managers relative to prescription drug plans and Medicare Advantage prescription drug plans (see S. 3729), S377 [29JA] NIH: establish National Institute for Biomedical Research and Development (see H.R. 7854), H2471 [5MR] Patient Protection and Affordable Care Act: ensure taxpayer funds for health insurance coverage are available only to U.S. citizens, nationals, or aliens lawfully present (see H.R. 7817), H2470 [5MR] Social Security: affirm importance to people of U.S. and express that it must be preserved, protected, and strengthened for current and future generations (see S. Res. 579), S115 [8JA] Women: allow greater access to safe and effective oral contraceptive drugs intended for routine use and direct GAO to conduct study on Federal funding of contraceptive methods (see H.R. 8083), H2710 [25MR] Remarks in House Abortion: prohibit chemical abortions, H1342 [22JA] CDC: disapprove revised immunization guidelines for children, H669 [13JA] Dept. of Veterans Affairs: interim rule relative to determining disability benefit eligibility, H2238 [23FE] Domestic policy: lower cost of consumer products and increase affordability, H2548 [17MR] FDA: publish final rule relative to nonclinical testing methods (S. 355), H941 [20JA] Health care professionals: tribute to pharmacists, H1989 [4FE] Insurance: improve services provided by pharmacy benefit managers, H2237 [23FE] Kennedy, Sec. of HHS: call for resignation, H911 [15JA] Medicare: assure pharmacy access and choice for beneficiaries (H.R. 4317), H928 [20JA] Myers, Wayne: Pennsylvania Pharmacists Association Pharmacist of the Year award recipient, H2487 [16MR] NIH: establish National Institute for Biomedical Research and Development (H.R. 7854), H2556 [18MR] Remarks in Senate Domestic policy: science and research funding, S246 [15JA] FDA: improve regulation of abortion drugs by prohibiting approval of new drugs, preventing labeling changes of existing drugs, and limiting dispensing of drugs remotely, by mail, or telemedicine (S. 3697), S292 [27JA] ------restore in-person dispensing requirements for chemical abortion drugs, S284 [27JA] Medicare: implementation of drug price negotiation program, S65 [7JA] Senate: legislative priorities, S560 [11FE] Social Security: affirm importance to people of U.S. and express that it must be preserved, protected, and strengthened for current and future generations (S. Res. 579), S119 [8JA] Texts of S. 3797, Prohibiting Tianeptine and Other Dangerous Products Act, S512 [5FE] S. Res. 579, affirm importance of Social Security to people of U.S. and express that it must be preserved, protected, and strengthened for current and future generations, S118 [8JA]